A 53-year-old patient who has maintained suppressed HIV RNA levels taking dolutegravir plus tenofovir DF-emtricitabine for several years is asking to switch to a one-tablet daily regimen and the clinician is considering a switch to the dual antiretroviral regimen of once-daily dolutegravir-lamivudine. Prior to starting their first antiretroviral regimen, the patient had a baseline HIV drug resistance genotype that showed no mutations. They have never had a virologic breakthrough.
Which one of the following statements is TRUE regarding this switch?
a. This switch should not be made if the person has chronic hepatitis C virus infection.
b. An archive (DNA) genotype should be performed prior to making the switch
c. For the switch to be safe, a person must have an estimated creatinine clearance above 90 mL/min
d. This switch should not be made if the person has chronic hepatitis B virus infection